AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02584712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Exercise Training
Description: This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
Study NCT03762460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online eHealth tool
Description: Mobile-optimized online eHealth tool to support MBC.
Study NCT03762460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Informational website
Description: Participants randomized to this group will receive information about online resources for mental health
Study NCT02376244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care cardiac rehabilitation according to current guidelines
Study NCT00575614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 1 mg o.d.
Study NCT00575614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: o.d.
Study NCT05363436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Providers had to prescribe 15 oxycodone pills to each patient discharge
Study NCT00373048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefloquine
Description: tablet, once weekly
Study NCT00373048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet, once weekly
Study NCT02281656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer
Study NCT02281656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.
Study NCT05225883 — intervention group
Intervention type: GENETIC
Intervention: GWAS
Description: This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study.
Study NCT01053533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines plus western therapy
Description: injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary
Study NCT01053533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: western therapy
Description: supportive therapy and antivirus therapy when necessary
Study NCT03190798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin 300mg
Description: Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets.
Study NCT03190798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Canagliflozin
Study NCT01352208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP9521
Description: oral
Study NCT02415140 — intervention group
Intervention type: OTHER
Intervention: Rate of depression
Study NCT00151424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Asenapine 5-10mgBID
Study NCT00151424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched against asenapine and olanzapine
Study NCT00151424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10-20 mg QD
Study NCT02031003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Infant formula
Description: Infant formula
Study NCT02031003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Infant formula
Study NCT01063348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
Study NCT01063348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules taken in same amount of pills as the active medication.
Study NCT03845829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In situ laser assisted fenestration
Description: In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
Study NCT02651116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: 15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
Study NCT02651116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mL Placebo
Study NCT02651116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough recording device
Description: FDA approved device validated for use in adults and children
Study NCT02651116 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cough recording device
Description: FDA approved device validated for use in adults and children
Study NCT02885103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high flow (NHF)
Description: NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
Study NCT02885103 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nebulizer
Description: Inhalation will be done will Nebulizer and via mouth
Study NCT00358852 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
Study NCT02701400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02701400 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT02701400 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT02701400 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT02701400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT01621854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-1031
Description: Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
Study NCT05918588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral
Study NCT05918588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral
Study NCT02524756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic nerve-sparing radical hysterectomy-type III/C1
Study NCT02524756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic radical hysterectomy (type III/C2).
Study NCT03373110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Based Cognitive Therapy
Description: see arm description
Study NCT03373110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioral Therapy
Description: see arm description
Study NCT03373110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Alone
Description: see arm description
Study NCT00730626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with 1X10E9 BB-12 and LA-5
Description: 100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
Study NCT00730626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with 1X10E10 BB-12 and LA-5
Description: 100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
Study NCT00730626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt Placebo
Description: 100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
Study NCT05349942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral scanning and data acquisition
Description: Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
Study NCT00676208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments
Description: Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
Study NCT03783338 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerobic exercises and Vitamin D supplementation
Description: Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks.
Study NCT03783338 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises and Vitamin D supplementation
Description: Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks.
Study NCT01930929 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Study NCT04239547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar Recruitment maneuver (ARM) +PEEP
Description: Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
Study NCT04239547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Following anesthesia induction and intubation, only 5 mmHg PEEP
Study NCT03921047 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03921047 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04294095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Baby My Move +
Description: This is a community-based, peer-led 12-week wellness intervention to decrease excessive gestational weight gain.
Study NCT04294095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This is a 12-week basic prenatal education class.
Study NCT02826993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCE in incomplete Colonoscopies
Description: When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
Study NCT01273493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.
Study NCT01273493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.
Study NCT01847612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indocyanine green fluorescent cholangiography
Study NCT01847612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Study NCT00067613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benchmarking Management Practices
Description: The Benchmarking intervention included:~1. Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~2. Training in Continuous Quality Improvement (CQI) Techniques~3. Review of best existing evidence~4. Site visits to the Centers with the Lowest Rates of BPD~5. Selection of Practices to change: Each site team selected practices for modification at their own center
Study NCT00067613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Management Practices
Description: Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
Study NCT02667457 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-rhAnnexin V-128
Study NCT03162458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaferon for children (liquid dosage form)
Description: 10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
Study NCT00707772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
Study NCT04102852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103
Description: probiotic administration at two different doses for 1 month
Study NCT01923623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine block
Study NCT01923623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine block
Study NCT03056820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 25° head-up position
Description: Participant will be positioned at 25° angle for procedure.
Study NCT03056820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 55° head-up position
Description: Participant will be positioned at 55° angle for procedure.
Study NCT02800213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
Study NCT02800213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
Study NCT02800213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
Study NCT02800213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
Study NCT02876575 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: A bipolar instrument for tonsillectomies
Description: A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
Study NCT03265366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
Study NCT03265366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
Study NCT03265366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
Study NCT03265366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT scan (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
Study NCT04336514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-compressed felt pad (SCF)
Description: Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
Study NCT03162458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (liquid dosage form)
Description: 10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
Study NCT01726283 — intervention group
Intervention type: DEVICE
Intervention: Corneal Cross-Linking
Description: Corneal cross-linking procedure conducted during vision correction surgery.
Study NCT01726283 — intervention group
Intervention type: DRUG
Intervention: Riboflavin
Description: Riboflavin will be instilled prior to corneal cross linking.
Study NCT03474432 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
Study NCT00672165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Description: A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
Study NCT01064141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
Description: 0.5 mL, Subcutaneous
Study NCT01064141 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines
Description: 0.5 mL, Subcutaneous and 0.5 mL, Intravascular